Healthcare / Drug Manufacturers - Specialty & GenericLSE
$93.00
-2.00 (-2.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $5.4M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
23.3x
↑EV/EBITDA
882.7x
↑ROE
2.0%
↑Gross Margin
45.1%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.1%
FCF CAGR
—
FCF margin
6.8%
FCF / Net income
3.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $79.6M · net income $1.7M · FCF $5.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $79.6M | $79.6M | $89.4M | $85.3M | $82.2M |
| Net Income | $1.7M | $1.7M | $1.0M | $1.0M | $-686000.00 |
| EBITDA | $7.3M | $7.3M | $6.5M | $7.4M | $3.7M |
| EPS | 0.02 | 0.02 | 0.02 | 0.01 | -0.01 |
| Gross Margin | 45.1% | 45.1% | 42.1% | 45.0% | 42.7% |
| Operating Margin | 4.2% | 4.2% | 4.7% | 5.8% | 4.3% |
| Net Margin | 2.1% | 2.1% | 1.2% | 1.2% | -0.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.05 | 0.02 |
| Current Ratio | 3.73 | 3.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.4M | $5.4M | $4.8M | $9.9M | $-3.4M |
| Returns | |||||
| ROE | 2.0% | 2.0% | 1.3% | 1.2% | -0.8% |
| Valuation | |||||
| P/E | 23.25 | 23.25 | 5592.11 | 6292.52 | — |
| EV/EBITDA | 882.73 | 882.73 | 895.98 | 850.28 | 2859.72 |
| P/B | 75.53 | 75.53 | 70.16 | 76.25 | 127.90 |
| Growth & Yield | |||||
| Revenue Growth | -11.0% | -11.0% | 4.8% | 3.8% | — |
| EPS Growth | 59.9% | 59.9% | 3.4% | 245.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
597.7%
EPS terminal req.
$8.25
Spread vs growth
-537.8%
5Y implied EPS CAGR
233.2%
EPS terminal req.
$9.99
Spread vs growth
-173.4%
10Y implied EPS CAGR
91.5%
EPS terminal req.
$16.08
Spread vs growth
-31.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+50.0%
Start / end P/E
4078.9x → 3827.2x
EPS bridge
0.02 → 0.02
Residual
-3.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.